Promomed Group received marketing authorization for a new drug for blood and bone marrow cancer
Bortezomib-Promomed, the drug product used for the treatment of multiple myeloma, received marketing authorization*. It is also prescribed to patients with mantle cell lymphoma** who have disease progression after several courses of treatment.
Bortezomib is a modified boric acid and is a proteasome inhibitor***. The mechanism of action of this drug is to accelerate protein cleavage and regulate the intracellular concentrations of proteins. Bortezomib affects cancer cells, leading to their death or inhibiting growth. Studies have shown that Bortezomib causes internal dysfunction in a large number of tumor cell types and causes tumor growth retardation, including multiple myeloma.
The development and production of medicinal products for the main critical diseases, including hematological malignancies, is one of the most important strategic areas for Promomed Group, a company focused on solving significant medical problems, saving and significantly improving the patients’ quality of life.
Bortezomib-Promomed is included in the List of Vital and Essential Drugs and will be manufactured in the form of lyophilizate for solution for intravenous and subcutaneous administration in a dosage of 2.5 to 3.5 mg, which corresponds to the standard treatment regimens.
*Myeloma is one of the forms of chronic lymphocytic leukemia, a hematological malignancy, which affects the flat bones, spine and kidneys and leads to serious disorders in the functioning of the immune system.
**Mantle cell lymphoma is a solid tumor of B-lymphocytes, a type of immune cells. It is a non-Hodgkin lymphoma, when a malignant tumor occurs not only in the lymph nodes, but also in the tonsils, spleen and other organs of our immune system.
***Proteasomes are enzymes that are found in all cells and play an important role in cell function and growth.
